TrialInternational journal of chronic obstructive pulmonary disease

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Timm Greulich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.